To assess the clinical relevance of PRMT5, immunohistochemistry (IHC) was performed on 194 nasopharyngeal carcinoma samples from chemotherapy-treated patients (Supplementary Tables S4 and S5). This evidence concerns the gene PRMT5 and nasopharyngeal carcinoma.